Sharad S. Singhal of the Beckman Institute, USA, published an article in Biochemical Pharmacology 2015 about a study on the outlook for 2′-hydroxysulfanones for the prevention of renal cell carcinoma. The article mentions that kidney cancer, also known as renal cell carcinoma (RCC), is one of the top 10 most prevalent cancers in the United States, and its incidence is increasing every year. Although significant advances have been made in drug treatment strategies for advanced kidney cancer, no approach has been found that can detect and cure renal cell carcinoma at an early stage. Renal cell carcinoma is insensitive to chemotherapy, and despite decades of diligent exploration, cytotoxic chemotherapy has not been effective in prolonging the lives of patients with renal cell carcinoma. RCC is also insensitive to radiotherapy, and radiotherapy is generally not used to prevent tumor recurrence and distant metastases. In the last few years, a large number of studies have confirmed the effectiveness of compounds of plant origin and their derivatives as anticancer agents. This research focuses on the use of the citrus-derived compound 2′-hydroxysulfanones to prevent renal cell carcinoma. Seventy-five percent of renal cell carcinomas are usually caused by mutations in the VHL gene. Often associated with smoking, long-term human exposure to tobacco carcinogens, such as N-dimethylnitrosamines and benzo(a)pyrene, causes mutations in the VHL gene in the body. Studies in preclinical mice have found that 2′-hydroxysulfanones protect the VHL gene and prevent VHL mutations, thereby preventing the development of renal cell carcinoma. Although clinical trials using 2′-hydroxysulfanones alone or in combination with other chemicals to prevent renal cell carcinoma have not been conducted, 2′-hydroxysulfanones and their derivatives are likely to be chemical agents for the prevention of renal cell carcinoma.